NDAORALSOLUTION
Approved
Dec 1999
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
4/8 — Partial
CELEXA (citalopram hydrobromide) by Forest Devices is unclear, but is presumed to be related to potentiation of serotonergic activity in the central nervous system (cns) resulting from its inhibition of cns neuronal reuptake of serotonin (5-ht). First approved in 1999.
Drug data last refreshed 48m ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CELEXA (citalopram hydrobromide) is an oral selective serotonin reuptake inhibitor (SSRI) approved in 1999 for depression treatment. It works by inhibiting the neuronal reuptake of serotonin (5-HT) in the central nervous system, thereby potentiating serotonergic activity. The exact mechanism remains incompletely understood but is presumed to relate to enhanced CNS serotonin availability.
$3MPart D
LOE ApproachingDeclining
Declining commercial trajectory with minimal Part D claims signals a shrinking brand team and limited growth opportunities as loss of exclusivity approaches.
Mechanism of Action
unclear, but is presumed to be related to potentiation of serotonergic activity in the central nervous system (CNS) resulting from its inhibition of CNS neuronal reuptake of serotonin (5-HT).
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Bioequivalence Study of Citalopram Hydrobromide Tablets 40 mg of Dr.Reddy's Laboratories Limited Under Fed Conditions
Started Oct 2003
24 enrolled
Healthy
Bioequivalence Study of Citalopram Hydrobromide Tablets 40 mg of Dr.Reddy's Laboratories Limited Under Fasting Conditions
Started Oct 2003
24 enrolled
Healthy
Career Relevance
Working on CELEXA offers limited career advancement opportunity given the product's LOE-approaching lifecycle and minimal linked job openings. Roles focus on managing decline, maximizing residual market value, and transitioning patients to generic alternatives rather than driving growth.
Brand Manager
Worked on CELEXA at Forest Devices? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.